Sep 27, 2021 7:00 am EDT Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
Sep 22, 2021 7:30 am EDT RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
Sep 3, 2021 5:00 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 12, 2021 7:00 am EDT Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
Jul 22, 2021 8:00 am EDT Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
Jul 9, 2021 5:00 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 30, 2021 7:15 am EDT Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints